BioSpace News Archive

Thermo Fisher Scientific Inc., the world leader in serving science, announced that its Board of Directors has declared a quarterly cash dividend of $0.22 per common share, payable on July 15, 2020, to shareholders of record as of June 15, 2020.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Federal District Court in Washington D.C. granted Vanda’s motion to dismiss a False Claims Act lawsuit filed against the company.

Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to announce that it recently received communication from the FDA stating that its 510(k) submission for its next generation Bioflux Software Device is now in the Substantiative Phase of the review process with an expected response by the end of June.

BeiGene, Ltd., a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced that the Company will present at the Bernstein 36th Annual Strategic Decisions Conference on Wednesday, May 27, 2020 at 8:00 a.m. ET.

MediWound Ltd., a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced financial results for the first quarter ended March 31, 2020 and provided business and financial updates related to the COVID-19 pandemic.

Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that the U.S. Food and Drug Administration approved the BRACAnalysis CDx® test for use as a companion diagnostic by healthcare professionals to identify men with metastatic castration-resistant prostate cancer who are eligible for treatment with Lynparza®.

Morgan Stanley executive brings extensive life sciences sector strategic and financial expertise to pioneering proteomics company

Spring Bank Pharmaceuticals, Inc. announced that a trial in progress poster will be presented for the Phase 1a/1b trial of the company’s intravenously-administered STING agonist candidate, SB 11285, at the American Society of Clinical Oncology Annual Meeting, which will be conducted virtually from May 29-June 2, 2020.

Phase 3b Study Evaluated Efficacy and Safety of ARISTADA® 2-month Dose, Together With ARISTADA INITIO® One-day Initiation Regimen, in Patients Hospitalized for Acute Schizophrenia

Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that Dr. David Giljohann, Chief Executive Officer of Exicure, will present at the virtual Jefferies 2020 Healthcare Conference on Thursday, June 4, 2020 at 1:00 p.m. EDT.